Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
3.110
-0.110 (-3.42%)
At close: Nov 13, 2026, 4:00 PM EST
2.950
-0.160 (-5.14%)
Pre-market: Nov 16, 2026, 7:29 AM EST

Entera Bio Earnings Call Transcripts

Fiscal Year 2026

  • EB613 met Phase II biomarker and BMD endpoints, and FDA alignment supports a 12-month placebo-controlled Phase III study plus a 12-month extension. A $27.5 million PIPE is intended to fund the program through PDUFA, with runway into 2030.

  • EB613, an oral anabolic peptide for osteoporosis, is advancing to a streamlined phase III trial after FDA alignment, targeting a major treatment gap between antiresorptives and injectables. The candidate aims to improve bone health for a broader patient population and offers strong pharmacoeconomic potential.

  • KOL event

    Experts highlighted a major treatment gap in osteoporosis due to injectable anabolic barriers, with strong demand for an oral option. EB613's phase II data show efficacy comparable to injectables, and its oral format could shift the treatment paradigm and improve patient access.

Fiscal Year 2025